Study of Electrical Prognostic Factors of Response to Intravenous Immunoglobulin Treatment in Chronic Inflammatory Demyelinating Polyradiculoneuropathy (PRONELEC PIDC)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03967899|
Recruitment Status : Not yet recruiting
First Posted : May 30, 2019
Last Update Posted : June 18, 2019
Chronic inflammatory demyelinating polyradiculoneuropathy (PIDC) is an acquired dysimmune polyneuropathy whose prevalence is estimated to be between 1 to 4 per 100,000 depending on the study, with an incidence of less than 1 per 100,000 per year. The clinical presentation of PIDC is heterogeneous, characterized by a symmetrical lesion predominating generally on large fibers, the most myelinated, responsible for ataxia and a motor deficit in the foreground. In the typical form, patients describe a proximal and distal motor or sensory deficit associated with isflexia that signifies a peripheral neurogenic syndrome.
The physiopathological hypothesis is that of an inflammation responsible for demyelinating nerve fibers, which results in electroneuromyogram (ENMG) by conduction abnormalities and histologically when a neuromuscular biopsy is performed by segmental demyelination.
Given the heterogeneity of the clinical presentation, electrical diagnostic criteria are proposed by the European Federation of Neurological Society in order to classify IPDCs into three categories: certain, probable and possible. In the absence of sufficient criteria to make the diagnosis of IPDC, it is also possible to use criteria of support, using a paraclinical report including the presence of an increase in protein (hyperproteinorachie) without cells for cerebrospinal fluid analysis, visualization of radicular inflammation on imaging (MRI of lumbar and / or brachial plexus), proximal peripheral involvement with somatosensory evoked potentials.
Therapeutically, a joint management between rehabilitation and the introduction of a background treatment allows the clinical improvement of certain patients. To date, the treatments proposed in first intention are corticosteroids, intravenous immunoglobulins (IVIg) and plasma exchanges. In fact, the efficacy of intravenous immunoglobulins has been widely shown by controlled and randomized therapeutic trials. Efficacy studies of IVIg in the literature are most often based on an assessment of clinical response after 24 weeks, but in clinical practice the response to treatment and continuation of treatment is often evaluated after 3 courses of treatment with the help of a clinical evaluation and the realization of an electroneuromyogram. These are administered in day hospitalization or traditional hospitalization, every four weeks, to patients whose diagnosis of PIDC has been established by electroneuromyogram according to the EFNS criteria.
Clinical prognostic factors for good response to IVIG therapy have been described in previous studies, including subacute disease, symmetrical involvement, and absence of amyotrophy.
In order to optimize the management of IPDCs, it is important to identify patients who respond to IVIg. Thus, the objective of our study is to look at the electroneuromyogram, the presence of electrical predictors of good response to treatment with IVIg.
|Condition or disease|
|Chronic Inflammatory Demyelinating Polyradiculoneuropathy|
|Study Type :||Observational|
|Estimated Enrollment :||40 participants|
|Official Title:||Study of Electrical Prognostic Factors of Response to Intravenous Immunoglobulin Treatment in Chronic Inflammatory Demyelinating Polyradiculoneuropathy|
|Estimated Study Start Date :||July 17, 2019|
|Estimated Primary Completion Date :||May 31, 2020|
|Estimated Study Completion Date :||September 30, 2020|
- Identify electromyographic predictors of treatment response [ Time Frame: Week 24 ]This corresponds to highlight, in the data of the electroneuromyogram performed before the initiation of treatment with IVIg, differences between the responder groups or not treatment [decrease of at least 1 point in the ONLS score], i.e three courses of IVIG.
- study of the demographic characteristics of patients followed for IPDC and treated with IVIg [ Time Frame: Week 24 ]This corresponds to percentage of patients with a certain / probable or possible IPDC.
- Clinical evidence of response to IVIG treatment [ Time Frame: Week 24 ]comparison of the results of the complementary explorations in the patients answering or not to the treatment
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03967899
|Contact: Pauline REACH, MD||0144126230 ext +email@example.com|
|Contact: Helene BEAUSSIER, PharmD, PhDfirstname.lastname@example.org|
|Groupe Hospitalier Paris Saint-Joseph||Not yet recruiting|
|Paris, France, 75014|
|Contact: Pauline REACH, MD 144127038 ext +33|
|Contact: Helene BEAUSSIER, PharmD, PhD 0144127883 ext +33 email@example.com|
|Principal Investigator:||Pauline REACH, MD||Groupe Hospitalier Paris Saint Joseph|